To assess the clinical potential of our molecular findings, we first focused on glioma cell lines with high p-AKT1/ENTPD5 levels and investigated if a reduction in white matter invasion upon SPARC depletion improves survival in a pre-clinical setting (Fig. 7a). The gene discussed is AKT1; the disease is central nervous system cancer.